Herein, we report a strategy to synthesize an Eu3+ doped single-phase monoclinic K3GdF6 double perovskite via a solid-state route with an average crystallite size of 18 ± 2.00 nm. Characterization methods such as X-ray diffraction, high-resolution transmission electron microscopy, X-ray photoelectron spectroscopy, and spectroscopic techniques provided a thorough understanding of the material's atomic and molecular-level structural, morphological, and functional properties. The photoluminescence study of K3GdF6:5% Eu3+ under different excitations such as 273, 393, 405, and 464 nm showed a hypersensitive, intense red emission at 613 nm and orange emission at 590 nm, which is a necessary parameter for high contrast imaging, particularly for overcoming autofluorescent background. The usage of K3GdF6:5% Eu3+ for spectral mapping and imaging has been specifically demonstrated through spatial photoluminescence mapping under 405 nm laser excitation. Moreover, the optical studies substantiated the occurrence of quantum cutting in K3GdF6:Eu3+ through systematic energy transfer between Gd3+ and Eu3+. Interestingly, in addition to optical attributes, the double perovskite showed superparamagnetic behavior at low temperature (2 K) with an average saturation magnetization of 96.86 emu/g. Through an exhaustive investigation of its optical and superparamagnetic properties, the synthesized double perovskite has been demonstrated to be a feasible choice for bioimaging (including optical and MRI), multiplexing detection, sensing, and other optical technologies.
No takes yet. Share an insight, caveat, or question.
Deo et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: